dexlansoprazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiulcer, benzimidazole derivatives 4162 138530-94-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dexlansoprazole sesquihydrate
  • R-Lansoprazole
  • (R)-Lansoprazole
  • dexlansoprazole
  • kapidex
  • dexilant
  • TAK-390
  • TAK-390MR
Dexlansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, dexlansoprazole has been characterized as a gastric proton-pump inhibitor, in that it blocks the final step of acid production.
  • Molecular weight: 369.36
  • Formula: C16H14F3N3O2S
  • CLOGP: 2.79
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 67.87
  • ALOGS: -3.17
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 30, 2009 FDA TAKEDA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic kidney disease 815.32 13.97 439 35636 41617 56214375
Tenosynovitis 232.53 13.97 127 35948 12334 56243658
End stage renal disease 231.30 13.97 101 35974 6010 56249982
Renal injury 227.49 13.97 112 35963 8775 56247217
Enthesopathy 207.53 13.97 102 35973 7961 56248031
Tongue disorder 172.75 13.97 97 35978 9939 56246053
Blood parathyroid hormone decreased 172.16 13.97 91 35984 8273 56247719
Rheumatoid nodule 166.38 13.97 109 35966 14748 56241244
Blood pressure systolic increased 165.26 13.97 165 35910 40671 56215321
Panniculitis 160.98 13.97 92 35983 9750 56246242
Red blood cell sedimentation rate 149.49 13.97 67 36008 4241 56251751
Granuloma skin 145.93 13.97 77 35998 6974 56249018
Tendonitis 144.71 13.97 108 35967 17989 56238003
Skin necrosis 144.08 13.97 93 35982 12268 56243724
Ulcer 130.16 13.97 111 35964 22374 56233618
Skin ulcer 120.68 13.97 136 35939 38472 56217520
Fear of injection 106.81 13.97 61 36014 6454 56249538
Alanine aminotransferase abnormal 106.32 13.97 53 36022 4262 56251730
Inflammation 97.89 13.97 166 35909 68905 56187087
Hypercalcaemia 96.06 13.97 99 35976 25312 56230680
Rash pruritic 94.65 13.97 141 35934 52453 56203539
Maternal exposure during pregnancy 91.89 13.97 8 36067 189545 56066447
Incorrect product administration duration 90.17 13.97 65 36010 10261 56245731
Drug eruption 87.84 13.97 95 35980 25668 56230324
Basal cell carcinoma 85.98 13.97 93 35982 25128 56230864
Pemphigus 75.21 13.97 7 36068 157205 56098787
Gastrooesophageal reflux disease 73.68 13.97 164 35911 83093 56172899
Exposure during pregnancy 71.14 13.97 4 36071 136338 56119654
Glossodynia 69.80 13.97 8 36067 152450 56103542
C-reactive protein abnormal 69.56 13.97 101 35974 36708 56219284
Total lung capacity increased 68.27 13.97 25 36050 934 56255058
Rebound acid hypersecretion 62.98 13.97 18 36057 298 56255694
Completed suicide 61.31 13.97 7 36068 133826 56122166
Forced expiratory volume decreased 59.13 13.97 37 36038 4623 56251369
Arthritis 58.30 13.97 168 35907 99684 56156308
Drug specific antibody 55.57 13.97 27 36048 2053 56253939
Peak expiratory flow rate decreased 55.06 13.97 19 36056 595 56255397
Erythema 54.54 13.97 221 35854 155718 56100274
Faeces soft 52.92 13.97 35 36040 4807 56251185
Granuloma 51.27 13.97 36 36039 5451 56250541
Drug interaction 51.13 13.97 36 36039 209719 56046273
Psoriatic arthropathy 49.62 13.97 131 35944 73877 56182115
Blood pressure fluctuation 49.40 13.97 91 35984 40269 56215723
Sputum discoloured 49.23 13.97 53 36022 14239 56241753
Endometriosis 49.01 13.97 33 36042 4669 56251323
Allergy to chemicals 48.73 13.97 26 36049 2407 56253585
Drug tolerance 48.41 13.97 36 36039 5958 56250034
Cervix neoplasm 46.25 13.97 13 36062 202 56255790
Toxicity to various agents 45.58 13.97 46 36029 224518 56031474
Swelling 45.46 13.97 52 36023 239719 56016273
Systemic lupus erythematosus 45.09 13.97 30 36045 180048 56075944
Red blood cell sedimentation rate increased 44.10 13.97 82 35993 36541 56219451
Loss of personal independence in daily activities 43.77 13.97 133 35942 81236 56174756
Arteriovenous fistula occlusion 43.01 13.97 14 36061 365 56255627
Obstructive airways disorder 42.65 13.97 54 36021 17228 56238764
Frustration tolerance decreased 42.25 13.97 34 36041 6319 56249673
Body temperature decreased 42.21 13.97 55 36020 18053 56237939
Renal failure 42.16 13.97 161 35914 110339 56145653
Blue toe syndrome 42.03 13.97 14 36061 393 56255599
Asthma 41.96 13.97 163 35912 112607 56143385
Somatic delusion 41.04 13.97 15 36060 557 56255435
Tubulointerstitial nephritis 41.01 13.97 52 36023 16613 56239379
Peripheral swelling 40.95 13.97 274 35801 234452 56021540
Headache 40.70 13.97 541 35534 558503 55697489
Rheumatoid lung 40.01 13.97 25 36050 3115 56252877
Joint injury 39.46 13.97 64 36011 25590 56230402
Blood pressure diastolic decreased 39.41 13.97 55 36020 19268 56236724
Thrombocytopenia 39.39 13.97 19 36056 136205 56119787
Hyponatraemia 38.64 13.97 9 36066 102130 56153862
Hepatic enzyme increased 38.45 13.97 32 36043 171352 56084640
Defaecation disorder 38.06 13.97 15 36060 687 56255305
Gastric disorder 37.07 13.97 72 36003 33138 56222854
Drug tolerance decreased 36.47 13.97 44 36031 13367 56242625
Cough 36.45 13.97 288 35787 259673 55996319
Neutropenia 36.14 13.97 29 36046 158138 56097854
Total lung capacity decreased 35.83 13.97 18 36057 1471 56254521
Echocardiogram abnormal 35.39 13.97 17 36058 1260 56254732
Chromaturia 34.87 13.97 46 36029 15279 56240713
Confusional state 34.43 13.97 50 36025 208105 56047887
Musculoskeletal disorder 33.95 13.97 51 36024 19096 56236896
Crepitations 33.48 13.97 31 36044 6953 56249039
Musculoskeletal stiffness 32.73 13.97 191 35884 155816 56100176
Dysphonia 32.01 13.97 78 35997 41869 56214123
Lung diffusion test decreased 31.86 13.97 13 36062 652 56255340
Pericarditis 31.78 13.97 15 36060 108908 56147084
Rhinorrhoea 31.39 13.97 94 35981 56943 56199049
Pancytopenia 31.30 13.97 9 36066 88706 56167286
Hypertensive nephropathy 31.03 13.97 12 36063 522 56255470
Respiration abnormal 30.91 13.97 27 36048 5614 56250378
Bronchopulmonary aspergillosis allergic 30.51 13.97 16 36059 1430 56254562
Death 28.71 13.97 117 35958 341309 55914683
Pulmonary thrombosis 28.02 13.97 30 36045 8007 56247985
Aspartate aminotransferase increased 27.99 13.97 116 35959 82486 56173506
Central obesity 27.95 13.97 14 36061 1137 56254855
Hand deformity 27.90 13.97 27 36048 134465 56121527
Bradycardia 27.49 13.97 5 36070 67499 56188493
Cardiac arrest 26.58 13.97 11 36064 86303 56169689
Antinuclear antibody positive 26.47 13.97 27 36048 6814 56249178
Tenosynovitis stenosans 26.42 13.97 18 36057 2596 56253396
Wound 26.39 13.97 30 36045 138774 56117218
Blood pressure systolic decreased 26.32 13.97 26 36049 6317 56249675
C-reactive protein increased 26.27 13.97 110 35965 78574 56177418
Abdominal pain 26.13 13.97 267 35808 258538 55997454
Lung opacity 25.77 13.97 17 36058 2324 56253668
Upper respiratory tract infection 25.66 13.97 102 35973 71186 56184806
Gastritis fungal 25.65 13.97 7 36068 97 56255895
Therapeutic reaction time decreased 24.91 13.97 15 36060 1749 56254243
Connective tissue inflammation 24.34 13.97 6 36069 54 56255938
Impaired healing 23.77 13.97 13 36062 86828 56169164
Renal pain 23.76 13.97 24 36051 5989 56250003
Forced vital capacity decreased 23.73 13.97 12 36063 994 56254998
Blood pressure diastolic abnormal 23.63 13.97 33 36042 11565 56244427
Synovial fluid analysis 23.62 13.97 15 36060 1923 56254069
Depressed level of consciousness 23.37 13.97 4 36071 56429 56199563
No adverse event 22.97 13.97 63 36012 36311 56219681
Parotid gland enlargement 22.93 13.97 11 36064 813 56255179
Gastrointestinal motility disorder 22.77 13.97 21 36054 4685 56251307
Abnormal faeces 22.54 13.97 21 36054 4747 56251245
Hyperkalaemia 22.45 13.97 3 36072 50862 56205130
Nocturia 22.13 13.97 25 36050 7081 56248911
Disease progression 21.94 13.97 21 36054 105152 56150840
Renal haemangioma 21.92 13.97 5 36070 31 56255961
Extra dose administered 21.91 13.97 22 36053 5451 56250541
Cardiac failure 21.46 13.97 13 36062 82080 56173912
Nephrogenic anaemia 21.38 13.97 14 36061 1890 56254102
Bladder disorder 21.28 13.97 26 36049 7998 56247994
Coma 21.13 13.97 6 36069 59649 56196343
Peak expiratory flow rate abnormal 21.01 13.97 6 36069 99 56255893
Scleritis 20.81 13.97 18 36057 3693 56252299
Cardio-respiratory arrest 20.67 13.97 5 36070 55316 56200676
Urine odour abnormal 20.61 13.97 22 36053 5852 56250140
Oropharyngeal pain 20.51 13.97 107 35968 83681 56172311
Alanine aminotransferase increased 20.49 13.97 116 35959 93546 56162446
Abdominal pain upper 20.45 13.97 189 35886 178124 56077868
Electrocardiogram QT prolonged 20.27 13.97 5 36070 54583 56201409
Platelet count decreased 20.21 13.97 23 36052 106360 56149632
Parapsoriasis 20.03 13.97 6 36069 118 56255874
Heart rate decreased 19.81 13.97 64 36011 40363 56215629
Regurgitation 19.60 13.97 12 36063 1442 56254550
Pulmonary embolism 19.46 13.97 24 36051 107100 56148892
Pharyngitis streptococcal 19.32 13.97 27 36048 9471 56246521
Stomatitis 19.01 13.97 30 36045 120780 56135212
Thoracic operation 18.98 13.97 6 36069 142 56255850
Patella fracture 18.85 13.97 13 36062 1912 56254080
Conjunctival haemorrhage 18.78 13.97 16 36059 3217 56252775
Acute kidney injury 18.68 13.97 236 35839 240527 56015465
Respiratory failure 18.67 13.97 20 36055 95042 56160950
Pulmonary toxicity 18.46 13.97 24 36051 7859 56248133
Nausea 18.43 13.97 629 35446 763549 55492443
Lung diffusion disorder 18.27 13.97 5 36070 70 56255922
Flail chest 18.21 13.97 5 36070 71 56255921
Brain hypoxia 18.19 13.97 8 36067 484 56255508
Type 2 diabetes mellitus 17.98 13.97 4 36071 46858 56209134
Nephropathy 17.93 13.97 20 36055 5589 56250403
Lung perforation 17.71 13.97 5 36070 79 56255913
Neutrophil count decreased 17.67 13.97 5 36070 49817 56206175
Delirium 17.64 13.97 3 36072 42514 56213478
Knee deformity 17.31 13.97 10 36065 1080 56254912
Dry mouth 17.12 13.97 84 35991 64121 56191871
Diarrhoea 17.03 13.97 532 35543 637975 55618017
Heart rate increased 16.83 13.97 101 35974 83172 56172820
Suicide attempt 16.81 13.97 8 36067 57828 56198164
Carcinoid tumour 16.67 13.97 7 36068 378 56255614
Dry throat 16.63 13.97 20 36055 6054 56249938
Pyrexia 16.59 13.97 180 35895 418593 55837399
Pulmonary fibrosis 16.32 13.97 49 36026 29709 56226283
Injection site oedema 16.27 13.97 10 36065 1210 56254782
Heart rate abnormal 16.04 13.97 17 36058 4486 56251506
Bone density decreased 15.90 13.97 29 36046 12731 56243261
Blood test abnormal 15.86 13.97 29 36046 12755 56243237
Pleuritic pain 15.77 13.97 21 36054 7036 56248956
Gout 15.51 13.97 28 36047 12193 56243799
Migraine 15.50 13.97 102 35973 86695 56169297
Heart rate irregular 15.29 13.97 38 36037 20641 56235351
Hypokalaemia 15.29 13.97 23 36052 94414 56161578
Malignant neoplasm progression 14.99 13.97 15 36060 73572 56182420
Deformity 14.98 13.97 25 36050 10230 56245762
Mental status changes 14.80 13.97 3 36072 37498 56218494
Humidity intolerance 14.63 13.97 6 36069 305 56255687
Thrombosis 14.62 13.97 76 35999 59351 56196641
International normalised ratio increased 14.58 13.97 5 36070 44036 56211956
Mononeuropathy 14.51 13.97 5 36070 156 56255836
Nasal congestion 14.50 13.97 73 36002 56297 56199695
Metabolic acidosis 14.46 13.97 4 36071 40450 56215542
Abortion spontaneous 14.43 13.97 5 36070 43748 56212244
Pain in extremity 14.36 13.97 269 35806 297162 55958830
Skin irritation 14.25 13.97 22 36053 8433 56247559
Sleep disorder due to general medical condition, insomnia type 14.21 13.97 5 36070 43333 56212659
Arthralgia 14.16 13.97 421 35654 501248 55754744
Eye haemorrhage 14.05 13.97 21 36054 7826 56248166
Insomnia 14.00 13.97 186 35889 191674 56064318

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic kidney disease 514.97 18.75 255 10807 37720 31648562
End stage renal disease 221.07 18.75 89 10973 8020 31678262
Renal injury 169.41 18.75 80 10982 10585 31675697
Tenosynovitis 160.49 18.75 59 11003 4151 31682131
Enthesopathy 155.78 18.75 58 11004 4229 31682053
Tongue disorder 126.20 18.75 52 11010 4965 31681317
C-reactive protein abnormal 119.45 18.75 57 11005 7712 31678570
Tendonitis 105.43 18.75 54 11008 8504 31677778
Synovitis 105.41 18.75 61 11001 12222 31674060
Alanine aminotransferase abnormal 99.38 18.75 41 11021 3926 31682356
Loss of personal independence in daily activities 81.11 18.75 72 10990 28216 31658066
Psoriatic arthropathy 78.67 18.75 61 11001 19822 31666460
Red blood cell sedimentation rate 72.90 18.75 23 11039 1013 31685269
Granuloma skin 70.92 18.75 23 11039 1108 31685174
Blood parathyroid hormone decreased 67.39 18.75 23 11039 1299 31684983
Panniculitis 60.51 18.75 23 11039 1773 31684509
Drug intolerance 58.46 18.75 81 10981 51952 31634330
Incorrect product administration duration 55.46 18.75 28 11034 4274 31682008
Rheumatoid nodule 54.83 18.75 24 11038 2657 31683625
Device dislocation 53.34 18.75 29 11033 5147 31681135
Occupational dermatitis 48.60 18.75 10 11052 72 31686210
Mobility decreased 47.30 18.75 53 11009 27416 31658866
Headache 47.24 18.75 156 10906 183496 31502786
Device malfunction 46.93 18.75 33 11029 9233 31677049
Treatment failure 46.55 18.75 64 10998 40728 31645554
Oesophageal polyp 45.90 18.75 9 11053 49 31686233
Occupational exposure to air contaminants 42.65 18.75 10 11052 139 31686143
Drug interaction 41.17 18.75 11 11051 208532 31477750
Inspiratory capacity abnormal 41.10 18.75 9 11053 90 31686192
Nerve degeneration 40.28 18.75 10 11052 179 31686103
Blood immunoglobulin E increased 39.32 18.75 18 11044 2213 31684069
Drug hypersensitivity 37.46 18.75 80 10982 72519 31613763
Nephrogenic anaemia 37.17 18.75 17 11045 2086 31684196
Airway remodelling 36.26 18.75 9 11053 161 31686121
Skin necrosis 35.69 18.75 23 11039 5575 31680707
Gastrooesophageal reflux disease 35.45 18.75 51 11011 33820 31652462
Stiff person syndrome 34.90 18.75 8 11054 100 31686182
Ulcer 33.12 18.75 25 11037 7796 31678486
Erythema 33.06 18.75 81 10981 80324 31605958
Renal failure 31.86 18.75 105 10957 123225 31563057
Asthma 30.58 18.75 54 11008 42557 31643725
Therapy non-responder 29.81 18.75 47 11015 33764 31652518
Erythema of eyelid 29.76 18.75 11 11051 784 31685498
Occupational exposure to product 29.40 18.75 9 11053 358 31685924
Micturition urgency 27.98 18.75 20 11042 5740 31680542
Aspartate aminotransferase increased 27.72 18.75 65 10997 62654 31623628
Neck pain 27.72 18.75 37 11025 22873 31663409
Terminal insomnia 27.58 18.75 9 11053 442 31685840
Hypertensive nephropathy 27.38 18.75 9 11053 452 31685830
Renal haemangioma 26.77 18.75 5 11057 20 31686262
Pain 26.53 18.75 132 10930 186627 31499655
Contraindicated product administered 25.58 18.75 33 11029 19739 31666543
Renal neoplasm 25.26 18.75 11 11051 1202 31685080
Renal mass 25.07 18.75 12 11050 1631 31684651
Bone density decreased 24.45 18.75 12 11050 1723 31684559
Stress 23.85 18.75 36 11026 24905 31661377
Thrombocytopenia 23.83 18.75 10 11052 142737 31543545
Neutropenia 23.17 18.75 10 11052 140354 31545928
Basal cell carcinoma 22.98 18.75 30 11032 18149 31668133
Alanine aminotransferase increased 22.41 18.75 67 10995 74589 31611693
Abdominal rigidity 21.89 18.75 10 11052 1223 31685059
Dyspnoea at rest 21.26 18.75 14 11048 3517 31682765
Hip surgery 20.91 18.75 9 11053 956 31685326
Skin ulcer 20.77 18.75 30 11032 19955 31666327
Drug abuse 20.69 18.75 3 11059 87755 31598527
Chronic kidney disease-mineral and bone disorder 20.65 18.75 7 11055 387 31685895
Dermatitis contact 20.37 18.75 13 11049 3097 31683185
Fatigue 19.87 18.75 191 10871 335015 31351267
Restrictive pulmonary disease 19.54 18.75 9 11053 1122 31685160
Rebound acid hypersecretion 19.52 18.75 5 11057 102 31686180
Rheumatoid lung 19.42 18.75 8 11054 762 31685520
Rash pruritic 19.36 18.75 32 11030 23906 31662376
Hypercalcaemia 19.10 18.75 24 11038 13976 31672306

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic kidney disease 662.90 14.56 418 39468 60639 70827919
Tenosynovitis 398.14 14.56 182 39704 13794 70874764
Enthesopathy 359.02 14.56 157 39729 10712 70877846
Tongue disorder 302.30 14.56 148 39738 13079 70875479
Tendonitis 258.84 14.56 159 39727 21963 70866595
Blood parathyroid hormone decreased 245.99 14.56 114 39772 8910 70879648
Rheumatoid nodule 241.88 14.56 133 39753 14934 70873624
End stage renal disease 231.98 14.56 117 39769 11016 70877542
Panniculitis 230.70 14.56 115 39771 10561 70877997
Red blood cell sedimentation rate 226.43 14.56 90 39796 4820 70883738
Granuloma skin 218.63 14.56 100 39786 7582 70880976
Alanine aminotransferase abnormal 195.66 14.56 94 39792 7965 70880593
Skin necrosis 187.79 14.56 116 39770 16175 70872383
Ulcer 169.95 14.56 130 39756 25624 70862934
Blood pressure systolic increased 165.72 14.56 182 39704 57077 70831481
C-reactive protein abnormal 161.94 14.56 150 39736 38429 70850129
Skin ulcer 148.01 14.56 158 39728 47987 70840571
Psoriatic arthropathy 144.28 14.56 180 39706 64591 70823967
Renal injury 139.85 14.56 96 39790 15998 70872560
Fear of injection 132.82 14.56 68 39818 6604 70881954
Rash pruritic 129.16 14.56 168 39718 62823 70825735
Basal cell carcinoma 124.28 14.56 122 39764 33576 70854982
Loss of personal independence in daily activities 119.03 14.56 189 39697 84721 70803837
Inflammation 118.49 14.56 181 39705 78484 70810074
Hypercalcaemia 113.08 14.56 117 39769 34268 70854290
Drug interaction 104.39 14.56 42 39844 381399 70507159
Drug eruption 99.73 14.56 117 39769 39379 70849179
Toxicity to various agents 96.82 14.56 47 39839 382125 70506433
Erythema 93.22 14.56 285 39601 199278 70689280
Headache 90.19 14.56 596 39290 579809 70308749
Gastrooesophageal reflux disease 84.46 14.56 169 39717 90670 70797888
Total lung capacity increased 71.82 14.56 25 39861 920 70887638
Peripheral swelling 70.91 14.56 292 39594 236271 70652287
Drug tolerance decreased 70.10 14.56 52 39834 9781 70878777
Asthma 69.46 14.56 186 39700 120607 70767951
Drug abuse 66.77 14.56 4 39882 147252 70741306
Thrombocytopenia 65.89 14.56 26 39860 239084 70649474
Granuloma 62.40 14.56 44 39842 7651 70880907
Rheumatoid lung 62.39 14.56 33 39853 3426 70885132
Neutropenia 61.54 14.56 34 39852 257122 70631436
Red blood cell sedimentation rate increased 59.69 14.56 90 39796 38552 70850006
Endometriosis 58.73 14.56 31 39855 3205 70885353
Drug tolerance 56.84 14.56 41 39845 7387 70881171
Arthritis 56.45 14.56 151 39735 97829 70790729
Aspartate aminotransferase increased 56.14 14.56 178 39708 126800 70761758
Peak expiratory flow rate decreased 56.07 14.56 19 39867 644 70887914
Allergy to chemicals 53.71 14.56 25 39861 1971 70886587
Drug specific antibody 52.91 14.56 26 39860 2313 70886245
Joint injury 52.34 14.56 70 39816 26862 70861696
Drug intolerance 51.46 14.56 257 39629 225430 70663128
Forced expiratory volume decreased 50.62 14.56 38 39848 7276 70881282
Blood pressure diastolic decreased 50.09 14.56 67 39819 25713 70862845
Maternal exposure during pregnancy 49.77 14.56 4 39882 115341 70773217
Pancytopenia 49.55 14.56 12 39874 151095 70737463
Cervix neoplasm 49.53 14.56 13 39873 177 70888381
Musculoskeletal disorder 48.48 14.56 58 39828 19913 70868645
Drug hypersensitivity 47.11 14.56 280 39606 262179 70626379
Rhinorrhoea 46.29 14.56 110 39776 66261 70822297
Sputum discoloured 44.54 14.56 54 39832 18797 70869761
Frustration tolerance decreased 44.28 14.56 34 39852 6731 70881827
Occupational dermatitis 44.06 14.56 11 39875 121 70888437
Faeces soft 43.64 14.56 34 39852 6876 70881682
Alanine aminotransferase increased 42.54 14.56 180 39706 147300 70741258
Nephrogenic anaemia 42.29 14.56 26 39860 3592 70884966
C-reactive protein increased 41.79 14.56 147 39739 110370 70778188
Defaecation disorder 41.61 14.56 15 39871 612 70887946
Hyponatraemia 41.53 14.56 19 39867 160068 70728490
Cardiac arrest 41.42 14.56 19 39867 159815 70728743
Bone density decreased 41.28 14.56 41 39845 11433 70877125
Synovitis 40.64 14.56 162 39724 129066 70759492
Blood pressure fluctuation 40.28 14.56 97 39789 58915 70829643
Somatic delusion 40.00 14.56 15 39871 685 70887873
Gastric disorder 39.71 14.56 69 39817 33253 70855305
Arteriovenous fistula occlusion 39.71 14.56 14 39872 535 70888023
Death 39.18 14.56 151 39735 509910 70378648
Blue toe syndrome 38.89 14.56 14 39872 569 70887989
Completed suicide 38.00 14.56 43 39843 227092 70661466
Respiratory failure 37.96 14.56 24 39862 168711 70719847
Fatigue 37.96 14.56 662 39224 823657 70064901
Hyperkalaemia 37.94 14.56 7 39879 106584 70781974
Occupational exposure to air contaminants 37.91 14.56 10 39876 139 70888419
Therapy non-responder 36.93 14.56 111 39775 76804 70811754
Rebound acid hypersecretion 36.83 14.56 9 39877 90 70888468
Blood pressure systolic decreased 35.62 14.56 35 39851 9636 70878922
Musculoskeletal stiffness 35.60 14.56 171 39715 147589 70740969
Oesophageal polyp 35.02 14.56 8 39878 58 70888500
Cardio-respiratory arrest 35.01 14.56 7 39879 100670 70787888
Coma 35 14.56 5 39881 91839 70796719
Dysphonia 34.89 14.56 83 39803 50017 70838541
Crepitations 34.85 14.56 33 39853 8681 70879877
Arthralgia 34.82 14.56 434 39452 502956 70385602
Rhabdomyolysis 34.71 14.56 6 39880 95754 70792804
Cough 34.52 14.56 306 39580 325071 70563487
Cardiac failure 34.28 14.56 19 39867 143522 70745036
Abdominal pain 33.89 14.56 317 39569 341810 70546748
Total lung capacity decreased 33.30 14.56 18 39868 1951 70886607
Disease progression 32.94 14.56 24 39862 156648 70731910
Depressed level of consciousness 32.76 14.56 5 39881 87426 70801132
Inspiratory capacity abnormal 32.47 14.56 8 39878 83 70888475
Obstructive airways disorder 32.34 14.56 55 39831 26058 70862500
Therapeutic product effect incomplete 32.02 14.56 143 39743 119739 70768819
Nerve degeneration 31.99 14.56 10 39876 261 70888297
Platelet count decreased 31.75 14.56 32 39854 178190 70710368
Respiration abnormal 31.35 14.56 28 39858 6836 70881722
Neutrophil count decreased 30.81 14.56 5 39881 83551 70805007
Confusional state 30.57 14.56 72 39814 284326 70604232
Bronchopulmonary aspergillosis allergic 30.54 14.56 17 39869 1952 70886606
Pyrexia 30.52 14.56 208 39678 606744 70281814
Tenosynovitis stenosans 30.46 14.56 18 39868 2315 70886243
Hypertensive nephropathy 30.07 14.56 13 39873 861 70887697
Body temperature decreased 29.87 14.56 56 39830 28616 70859942
Oropharyngeal pain 28.89 14.56 119 39767 96191 70792367
Nausea 28.36 14.56 652 39234 851436 70037122
Sepsis 27.83 14.56 60 39826 244485 70644073
Echocardiogram abnormal 27.77 14.56 16 39870 1963 70886595
Pulmonary embolism 27.74 14.56 28 39858 155839 70732719
Anaemia 27.49 14.56 125 39761 403298 70485260
Incorrect product administration duration 27.20 14.56 32 39854 10792 70877766
Blood pressure diastolic abnormal 26.67 14.56 38 39848 15466 70873092
Electrocardiogram QT prolonged 26.66 14.56 7 39879 83510 70805048
Renal neoplasm 26.50 14.56 15 39871 1779 70886779
Multiple organ dysfunction syndrome 26.44 14.56 14 39872 108501 70780057
Pemphigus 26.43 14.56 7 39879 83029 70805529
Pulmonary thrombosis 26.30 14.56 32 39854 11176 70877382
Glossodynia 26.22 14.56 8 39878 86479 70802079
Device malfunction 26.05 14.56 42 39844 19042 70869516
Synovial fluid analysis 25.93 14.56 15 39871 1854 70886704
Airway remodelling 25.88 14.56 8 39878 201 70888357
Lung diffusion test decreased 25.68 14.56 13 39873 1232 70887326
Nasopharyngitis 25.65 14.56 213 39673 221993 70666565
Pain in extremity 25.34 14.56 289 39597 327793 70560765
Treatment failure 25.32 14.56 153 39733 143989 70744569
Occupational exposure to product 25.23 14.56 11 39875 744 70887814
Hypokalaemia 25.19 14.56 22 39864 131166 70757392
Renal pain 25.14 14.56 26 39860 7604 70880954
Lung opacity 25.05 14.56 19 39867 3694 70884864
Seizure 24.37 14.56 39 39847 177923 70710635
Delirium 24.31 14.56 6 39880 74608 70813950
Pulmonary fibrosis 24.06 14.56 57 39829 34253 70854305
Blood test abnormal 23.99 14.56 35 39851 14555 70874003
Lactic acidosis 23.73 14.56 4 39882 65020 70823538
International normalised ratio increased 23.53 14.56 8 39878 80718 70807840
Deformity 23.34 14.56 26 39860 8271 70880287
Scleritis 23.26 14.56 18 39868 3604 70884954
Abdominal pain upper 23.11 14.56 187 39699 193415 70695143
Heart rate decreased 23.01 14.56 82 39804 61933 70826625
Central obesity 22.60 14.56 13 39873 1590 70886968
Metabolic acidosis 22.31 14.56 7 39879 74339 70814219
Blood pressure diastolic increased 22.25 14.56 31 39855 12360 70876198
Medication error 21.91 14.56 3 39883 56909 70831649
Peak expiratory flow rate abnormal 21.84 14.56 6 39880 98 70888460
Stomatitis 21.84 14.56 24 39862 128487 70760071
Hypoglycaemia 21.80 14.56 13 39873 94351 70794207
Stiff person syndrome 21.68 14.56 8 39878 349 70888209
Hypotension 21.59 14.56 136 39750 404245 70484313
Heart rate increased 21.47 14.56 117 39769 106031 70782527
Therapeutic reaction time decreased 21.40 14.56 15 39871 2582 70885976
Abnormal faeces 20.94 14.56 22 39864 6551 70882007
Renal failure 20.63 14.56 179 39707 188891 70699667
Pharyngitis streptococcal 20.61 14.56 26 39860 9422 70879136
Heart rate irregular 20.41 14.56 49 39837 29694 70858864
Respiratory arrest 20.40 14.56 3 39883 53930 70834628
Device dependence 20.37 14.56 5 39881 51 70888507
Gastrointestinal motility disorder 20.23 14.56 20 39866 5546 70883012
Infusion related reaction 20.01 14.56 184 39702 197350 70691208
Urine odour abnormal 20.00 14.56 20 39866 5623 70882935
Chronic kidney disease-mineral and bone disorder 19.94 14.56 9 39877 661 70887897
Forced vital capacity decreased 19.93 14.56 12 39874 1597 70886961
Device dislocation 19.86 14.56 41 39845 22466 70866092
Blood pressure increased 19.81 14.56 177 39709 188340 70700218
Osteomyelitis 19.79 14.56 49 39837 30269 70858289
Suicide attempt 19.75 14.56 10 39876 79500 70809058
Patella fracture 19.67 14.56 12 39874 1634 70886924
Systemic lupus erythematosus 19.67 14.56 17 39869 101885 70786673
Stress 19.61 14.56 83 39803 67883 70820675
Knee deformity 19.37 14.56 10 39876 988 70887570
Pericarditis 19.11 14.56 12 39874 84693 70803865
Terminal insomnia 19.07 14.56 10 39876 1020 70887538
Pain 18.98 14.56 475 39411 628341 70260217
Gamma-glutamyltransferase increased 18.76 14.56 3 39883 50682 70837876
Drug ineffective 18.69 14.56 674 39212 939078 69949480
Erythema of eyelid 18.68 14.56 13 39873 2212 70886346
Chromaturia 18.61 14.56 41 39845 23487 70865071
Respiratory distress 18.59 14.56 4 39882 54646 70833912
Dyspepsia 18.57 14.56 99 39787 88978 70799580
Wheezing 18.51 14.56 103 39783 94067 70794491
Mobility decreased 18.51 14.56 110 39776 102889 70785669
Product use issue 18.42 14.56 168 39718 179769 70708789
Intentional overdose 18.30 14.56 17 39869 98418 70790140
Cardiac failure congestive 18.25 14.56 30 39856 135427 70753131
Gastritis fungal 18.18 14.56 6 39880 187 70888371
Thoracic operation 18.06 14.56 6 39880 191 70888367
Dry mouth 18.02 14.56 83 39803 70374 70818184
Flail chest 17.96 14.56 5 39881 86 70888472
Carcinoid tumour 17.85 14.56 8 39878 578 70887980
Injection site oedema 17.84 14.56 10 39876 1164 70887394
Lung perforation 17.70 14.56 5 39881 91 70888467
Bradycardia 17.35 14.56 27 39859 124588 70763970
Unresponsive to stimuli 17.26 14.56 4 39882 51927 70836631
Mental status changes 17.13 14.56 7 39879 63094 70825464
Hyperparathyroidism secondary 17.06 14.56 13 39873 2545 70886013
Plasma cell myeloma 17.03 14.56 10 39876 73191 70815367
Septic shock 16.93 14.56 23 39863 112235 70776323
Bladder disorder 16.80 14.56 22 39864 8267 70880291
Back pain 16.69 14.56 229 39657 270923 70617635
Ear infection 16.64 14.56 44 39842 28292 70860266
Therapeutic response decreased 16.57 14.56 71 39815 58382 70830176
Upper respiratory tract infection 16.45 14.56 88 39798 79186 70809372
Neuropathy peripheral 16.27 14.56 29 39857 126867 70761691
Impaired healing 16.14 14.56 11 39875 74363 70814195
Muscle strain 15.95 14.56 22 39864 8688 70879870
Synovial cyst 15.89 14.56 22 39864 8720 70879838
Therapeutic response shortened 15.84 14.56 27 39859 12811 70875747
Blister 15.77 14.56 20 39866 100506 70788052
Pleuritic pain 15.59 14.56 22 39864 8875 70879683
Lung diffusion disorder 15.56 14.56 5 39881 143 70888415
Migraine 15.54 14.56 81 39805 72157 70816401
Hepatotoxicity 15.41 14.56 3 39883 43983 70844575
Blood immunoglobulin E increased 15.33 14.56 16 39870 4728 70883830
Pneumonia aspiration 15.22 14.56 8 39878 62281 70826277
Feeling jittery 15.21 14.56 25 39861 11518 70877040
Nasal congestion 15.08 14.56 75 39811 65597 70822961
Blood alkaline phosphatase increased 15.08 14.56 7 39879 58514 70830044
Pulmonary toxicity 15.06 14.56 24 39862 10774 70877784
Fall 14.82 14.56 169 39717 443927 70444631
Hyperglycaemia 14.81 14.56 9 39877 64663 70823895
Impaired work ability 14.69 14.56 30 39856 16310 70872248
Joint effusion 14.61 14.56 29 39857 15448 70873110
Humidity intolerance 14.60 14.56 6 39880 350 70888208
Gastrointestinal haemorrhage 14.57 14.56 35 39851 137373 70751185

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02BC06 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Proton pump inhibitors
FDA MoA N0000000147 Proton Pump Inhibitors
FDA EPC N0000175525 Proton Pump Inhibitor
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D054328 Proton Pump Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Peptic ulcer indication 13200003 DOID:750
Erosive esophagitis indication 40719004
Gastroesophageal reflux disease indication 235595009 DOID:8534
Maintenance of Healing Erosive Esophagitis indication
Duodenal ulcer disease off-label use 51868009 DOID:1724
Zollinger-Ellison syndrome off-label use 53132006 DOID:0050782
Gastric ulcer off-label use 397825006 DOID:10808
Duodenal Ulcer due to H. Pylori off-label use
Maintenance of Healing Duodenal Ulcer off-label use
NSAID-Induced Gastric Ulcer off-label use
Prevention of NSAID-Induced Gastric Ulcer off-label use
Pathological Gastric Hypersecretory Condition off-label use
Osteoporosis contraindication 64859006 DOID:11476
Fracture of bone contraindication 125605004
Hypomagnesemia contraindication 190855004
Disease of liver contraindication 235856003 DOID:409




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.23 acidic
pKa2 3.35 Basic
pKa3 2.72 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG DEXILANT SOLUTAB TAKEDA PHARMS USA N208056 Jan. 26, 2016 DISCN TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG DEXILANT SOLUTAB TAKEDA PHARMS USA N208056 Jan. 26, 2016 DISCN TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE ORAL 6664276 Jan. 30, 2023 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8784885 Oct. 15, 2023 TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 8173158 March 17, 2030 TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS
30MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 9233103 March 5, 2032 USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS
60MG DEXILANT TAKEDA PHARMS USA N022287 Jan. 30, 2009 RX CAPSULE, DELAYED RELEASE ORAL 9233103 March 5, 2032 USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Potassium-transporting ATPase Transporter INHIBITOR CHEMBL CHEMBL
Cytosolic endo-beta-N-acetylglucosaminidase Enzyme IC50 4.60 CHEMBL
Sterile alpha and TIR motif-containing protein 1 Unclassified IC50 5.48 CHEMBL

External reference:

IDSource
4028570 VUID
N0000189452 NUI
D08903 KEGG_DRUG
313640-86-7 SECONDARY_CAS_RN
4028570 VANDF
C2348248 UMLSCUI
CHEBI:135931 CHEBI
CHEMBL1201863 ChEMBL_ID
D064748 MESH_DESCRIPTOR_UI
DB05351 DRUGBANK_ID
5487 IUPHAR_LIGAND_ID
8524 INN_ID
UYE4T5I70X UNII
9578005 PUBCHEM_CID
816346 RXNORM
160770 MMSL
172755 MMSL
26184 MMSL
356045 MMSL
d07395 MMSL
012953 NDDF
441863009 SNOMEDCT_US
442540007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 24979-703 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA AUTHORIZED GENERIC 33 sections
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 24979-703 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA AUTHORIZED GENERIC 33 sections
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 24979-704 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA AUTHORIZED GENERIC 33 sections
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 24979-704 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA AUTHORIZED GENERIC 33 sections
Dexlansoprazole HUMAN PRESCRIPTION DRUG LABEL 1 49884-148 CAPSULE, DELAYED RELEASE 60 mg ORAL ANDA 28 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 50090-4374 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA 32 sections
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 50090-5944 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA AUTHORIZED GENERIC 32 sections
Dexlansoprazole delayed release HUMAN PRESCRIPTION DRUG LABEL 1 50090-5956 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA AUTHORIZED GENERIC 32 sections
Kapidex HUMAN PRESCRIPTION DRUG LABEL 1 54868-5998 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA 16 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 54868-6152 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA 31 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 55154-5154 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA 31 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 64764-171 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA 33 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 64764-171 CAPSULE, DELAYED RELEASE 30 mg ORAL NDA 33 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 64764-175 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA 33 sections
Dexilant HUMAN PRESCRIPTION DRUG LABEL 1 64764-175 CAPSULE, DELAYED RELEASE 60 mg ORAL NDA 33 sections